Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 5/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR1B | P28222 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355686 | 0.85 | HTR1D (0.43) | HSD11B1CA1CA2HTR1DHTR1A | |
| SCHEMBL8900273 | 0.82 | L3MBTL1 (0.47) | HSD11B1CA1CA2HTR1DHTR1A | |
| SCHEMBL17539934 | 0.81 | CXCR2 (0.43) | TDP1HSD11B1CA1CA2HTR1D | |
| SCHEMBL11702159 | 0.81 | ALDH1A1 (0.45) | HSD11B1CA1CA2HTR1DHTR1A | |
| SCHEMBL10073222 | 0.80 | CXCR2 (0.40) | HSD11B1CA1CA2HTR1DHTR1A | |
| SCHEMBL1748180 | 0.80 | HSD11B1 (0.56) | HSD11B1CA1CA2HTR1DHTR1A | |
| SCHEMBL13251162 | 0.80 | HTR1D (0.45) | HSD11B1CA1CA2HTR1DHTR1A | |
| SCHEMBL27351302 | 0.80 | HSD11B1 (0.56) | HSD11B1POLBCA1CA2HTR1D | |
| SCHEMBL4056753 | 0.79 | CA1 (0.51) | TDP1HSD11B1CA1CA2HTR1D | |
| SCHEMBL576035 | 0.79 | CA2 (0.50) | HSD11B1CA1CA2HTR1DHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2949655-B1 | REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | HOKKO CHEM IND CO (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-9707551-B2 | Reaction catalyst for cross-coupling and method for manufacturing aromatic compound | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150360214-A1 | REACTION CATALYST FOR CROSS-COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| EP-2949655-A1 | REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | Hokko Chemical Industry Co., Ltd. (JP) | 2015-12-02 | — | — | EP | disclosed |
| CN-105008378-A | Reaction catalyst for cross coupling and method for manufacturing aromatic compound | HOKKO CHEM IND CO | 2015-10-28 | — | — | CN | disclosed |
| EP-1167372-B1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO PERFUMERY CO LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6365776-B1 | FROM ORGANOHALOGEN COMPOUND AND AMINE USING PALLADIUM COMPOUND CATALYST AND PROMOTER | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-04-02 | — | — | US | disclosed |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TAKASAGO INTERNATIONAL CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TYR, DDC, PNMT | TDP1 3847/4885HSD11B1 4181/4885POLB 2990/4885 |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | TDP1 3460/4885HSD11B1 4574/4885POLB 1957/4885 |
| US-20150360214-A1 | REACTION CATALYST FOR CROSS-COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | ALK, HRH4, HRH3 | TDP1 4138/4885HSD11B1 3131/4885POLB 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.